(Q33405714)

English

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

D J DeAngelo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Spencer

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K N Bhalla

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H M Prince

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

T Fischer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

T Kindler

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

F J Giles

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J W Scott

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K Parker

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Liu

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Woo

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

P Atadja

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K K Mishra

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

6 February 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1628-1636

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2013.38

0 references

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

The molecular biology of mixed lineage leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

H3K79 methylation profiles define murine and human MLL-AF4 leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Bortezomib for AL amyloidosis: moving forward

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

StatBite: FDA oncology drug product approvals in 2009

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.38

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33405714&oldid=1607221709"